This protocol addresses patients with pulmonary sarcoidosis who present with mild respiratory symptoms — specifically cough — without dyspnea. This symptom profile defines a distinct clinical subset that guides initial therapeutic decisions.
Patients present with pulmonary sarcoidosis accompanied by mild cough. The absence of dyspnea indicates a less severe but clinically relevant disease burden. Recognising this presentation is essential for selecting an appropriately calibrated treatment approach rather than over- or under-treating.
For mild symptoms such as cough, a corticosteroid-based strategy is employed — beginning with an inhaled route, with oral corticosteroid therapy considered if the initial approach does not produce an adequate response.
Improvement in forced vital capacity is the primary functional goal, with response typically assessed within the first one to three months of therapy.
For patients with mild symptoms, such as a cough, treatment should begin with inhaled corticosteroids.
If there is no response, oral corticosteroids can be considered.
Once corticosteroids have been started, the patient is usually seen 1–3 months.
View source ↗